Skip to main content
Journal ArticleOPEN ACCESS

Siponimod for treating secondary progressive multiple sclerosis

  • Chaplin S
Prescriber (2020) 31(11-12) 34-35
DOI: 10.1002/psb.1882
N/ACitations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Siponimod (Mayzent) is a sphingosine‐1‐phosphate receptor modulator for the treatment of secondary progressive multiple sclerosis. This article discusses its properties, place in therapy, efficacy and adverse effects.

Cite

CITATION STYLE

APA

Chaplin, S. (2020). Siponimod for treating secondary progressive multiple sclerosis. Prescriber, 31(11–12), 34–35. https://doi.org/10.1002/psb.1882

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free